 | • レポートコード：MRC2-11QY03769 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、111ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は心血管疾患治療薬のグローバル市場について調査・分析したレポートです。種類別（ヘパリン、クマディン、セクトラル、ゼベタ、ロプレッサー、トプロロールXL、ノルバスク、ロトレル、その他）市場規模、用途別（虚血性心疾患、脂質異常症、脳卒中、血栓症、アテローム性動脈硬化症、冠状動脈疾患、末梢動脈疾患、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別心血管疾患治療薬の競争状況、市場シェア ・世界の心血管疾患治療薬市場：種類別市場規模 2015年-2020年（ヘパリン、クマディン、セクトラル、ゼベタ、ロプレッサー、トプロロールXL、ノルバスク、ロトレル、その他） ・世界の心血管疾患治療薬市場：種類別市場規模予測 2021年-2026年（ヘパリン、クマディン、セクトラル、ゼベタ、ロプレッサー、トプロロールXL、ノルバスク、ロトレル、その他） ・世界の心血管疾患治療薬市場：用途別市場規模 2015年-2020年（虚血性心疾患、脂質異常症、脳卒中、血栓症、アテローム性動脈硬化症、冠状動脈疾患、末梢動脈疾患、その他） ・世界の心血管疾患治療薬市場：用途別市場規模予測 2021年-2026年（虚血性心疾患、脂質異常症、脳卒中、血栓症、アテローム性動脈硬化症、冠状動脈疾患、末梢動脈疾患、その他） ・北米の心血管疾患治療薬市場分析：米国、カナダ ・ヨーロッパの心血管疾患治療薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの心血管疾患治療薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の心血管疾患治療薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの心血管疾患治療薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：AstraZeneca、Johnson＆Johnson、Pfizer、Sanofi、Merck、Daiichi Sankyo Company Limited、Novartis、Bayer、Takeda Pharmaceutical、Hoffmann-La Roche、United Therapeutics Corporation、Actelion Pharmaceuticals、Boehringer Ingelheim、Astellas Pharma ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Market Analysis and Insights: Global Cardiovascular Disease Drugs Market
The global Cardiovascular Disease Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Cardiovascular Disease Drugs Scope and Market Size
Cardiovascular Disease Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Cardiovascular Disease Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Cardiovascular Disease Drugs market is segmented into
Heparin
Coumadin
Sectral
Zebeta
Lopressor
Toprol XL
Norvasc
Lotrel
Others
Segment by Application, the Cardiovascular Disease Drugs market is segmented into
Asischemic Heart Disease
Dyslipidemia
Stroke
Thrombosis
Atherosclerosis
Coronary Artery Diseases
Peripheral Artery Disease
Others
Regional and Country-level Analysis
The Cardiovascular Disease Drugs market is analysed and market size information is provided by regions (countries).
The key regions covered in the Cardiovascular Disease Drugs market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Cardiovascular Disease Drugs Market Share Analysis
Cardiovascular Disease Drugs market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Cardiovascular Disease Drugs business, the date to enter into the Cardiovascular Disease Drugs market, Cardiovascular Disease Drugs product introduction, recent developments, etc.
The major vendors covered:
AstraZeneca
Johnson＆Johnson
Pfizer
Sanofi
Merck
Daiichi Sankyo Company Limited
Novartis
Bayer
Takeda Pharmaceutical
Hoffmann-La Roche
United Therapeutics Corporation
Actelion Pharmaceuticals
Boehringer Ingelheim
Astellas Pharma
1 Study Coverage
1.1 Cardiovascular Disease Drugs Product Introduction
1.2 Market Segments
1.3 Key Cardiovascular Disease Drugs Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Cardiovascular Disease Drugs Market Size Growth Rate by Type
1.4.2 Heparin
1.4.3 Coumadin
1.4.4 Sectral
1.4.5 Zebeta
1.4.6 Lopressor
1.4.7 Toprol XL
1.4.8 Norvasc
1.4.9 Lotrel
1.4.10 Others
1.5 Market by Application
1.5.1 Global Cardiovascular Disease Drugs Market Size Growth Rate by Application
1.5.2 Asischemic Heart Disease
1.5.3 Dyslipidemia
1.5.4 Stroke
1.5.5 Thrombosis
1.5.6 Atherosclerosis
1.5.7 Coronary Artery Diseases
1.5.8 Peripheral Artery Disease
1.5.9 Others
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Cardiovascular Disease Drugs Market Size, Estimates and Forecasts
2.1.1 Global Cardiovascular Disease Drugs Revenue 2015-2026
2.1.2 Global Cardiovascular Disease Drugs Sales 2015-2026
2.2 Global Cardiovascular Disease Drugs, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Cardiovascular Disease Drugs Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Cardiovascular Disease Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Cardiovascular Disease Drugs Competitor Landscape by Players
3.1 Cardiovascular Disease Drugs Sales by Manufacturers
3.1.1 Cardiovascular Disease Drugs Sales by Manufacturers (2015-2020)
3.1.2 Cardiovascular Disease Drugs Sales Market Share by Manufacturers (2015-2020)
3.2 Cardiovascular Disease Drugs Revenue by Manufacturers
3.2.1 Cardiovascular Disease Drugs Revenue by Manufacturers (2015-2020)
3.2.2 Cardiovascular Disease Drugs Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Cardiovascular Disease Drugs Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Cardiovascular Disease Drugs Revenue in 2019
3.2.5 Global Cardiovascular Disease Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Cardiovascular Disease Drugs Price by Manufacturers
3.4 Cardiovascular Disease Drugs Manufacturing Base Distribution, Product Types
3.4.1 Cardiovascular Disease Drugs Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Cardiovascular Disease Drugs Product Type
3.4.3 Date of International Manufacturers Enter into Cardiovascular Disease Drugs Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Cardiovascular Disease Drugs Market Size by Type (2015-2020)
4.1.1 Global Cardiovascular Disease Drugs Sales by Type (2015-2020)
4.1.2 Global Cardiovascular Disease Drugs Revenue by Type (2015-2020)
4.1.3 Cardiovascular Disease Drugs Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Cardiovascular Disease Drugs Market Size Forecast by Type (2021-2026)
4.2.1 Global Cardiovascular Disease Drugs Sales Forecast by Type (2021-2026)
4.2.2 Global Cardiovascular Disease Drugs Revenue Forecast by Type (2021-2026)
4.2.3 Cardiovascular Disease Drugs Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Cardiovascular Disease Drugs Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Cardiovascular Disease Drugs Market Size by Application (2015-2020)
5.1.1 Global Cardiovascular Disease Drugs Sales by Application (2015-2020)
5.1.2 Global Cardiovascular Disease Drugs Revenue by Application (2015-2020)
5.1.3 Cardiovascular Disease Drugs Price by Application (2015-2020)
5.2 Cardiovascular Disease Drugs Market Size Forecast by Application (2021-2026)
5.2.1 Global Cardiovascular Disease Drugs Sales Forecast by Application (2021-2026)
5.2.2 Global Cardiovascular Disease Drugs Revenue Forecast by Application (2021-2026)
5.2.3 Global Cardiovascular Disease Drugs Price Forecast by Application (2021-2026)
6 North America
6.1 North America Cardiovascular Disease Drugs by Country
6.1.1 North America Cardiovascular Disease Drugs Sales by Country
6.1.2 North America Cardiovascular Disease Drugs Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Cardiovascular Disease Drugs Market Facts & Figures by Type
6.3 North America Cardiovascular Disease Drugs Market Facts & Figures by Application
7 Europe
7.1 Europe Cardiovascular Disease Drugs by Country
7.1.1 Europe Cardiovascular Disease Drugs Sales by Country
7.1.2 Europe Cardiovascular Disease Drugs Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Cardiovascular Disease Drugs Market Facts & Figures by Type
7.3 Europe Cardiovascular Disease Drugs Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Cardiovascular Disease Drugs by Region
8.1.1 Asia Pacific Cardiovascular Disease Drugs Sales by Region
8.1.2 Asia Pacific Cardiovascular Disease Drugs Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Cardiovascular Disease Drugs Market Facts & Figures by Type
8.3 Asia Pacific Cardiovascular Disease Drugs Market Facts & Figures by Application
9 Latin America
9.1 Latin America Cardiovascular Disease Drugs by Country
9.1.1 Latin America Cardiovascular Disease Drugs Sales by Country
9.1.2 Latin America Cardiovascular Disease Drugs Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Cardiovascular Disease Drugs Market Facts & Figures by Type
9.3 Central & South America Cardiovascular Disease Drugs Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Cardiovascular Disease Drugs by Country
10.1.1 Middle East and Africa Cardiovascular Disease Drugs Sales by Country
10.1.2 Middle East and Africa Cardiovascular Disease Drugs Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Cardiovascular Disease Drugs Market Facts & Figures by Type
10.3 Middle East and Africa Cardiovascular Disease Drugs Market Facts & Figures by Application
11 Company Profiles
11.1 AstraZeneca
11.1.1 AstraZeneca Corporation Information
11.1.2 AstraZeneca Description and Business Overview
11.1.3 AstraZeneca Sales, Revenue and Gross Margin (2015-2020)
11.1.4 AstraZeneca Cardiovascular Disease Drugs Products Offered
11.1.5 AstraZeneca Related Developments
11.2 Johnson＆Johnson
11.2.1 Johnson＆Johnson Corporation Information
11.2.2 Johnson＆Johnson Description and Business Overview
11.2.3 Johnson＆Johnson Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Johnson＆Johnson Cardiovascular Disease Drugs Products Offered
11.2.5 Johnson＆Johnson Related Developments
11.3 Pfizer
11.3.1 Pfizer Corporation Information
11.3.2 Pfizer Description and Business Overview
11.3.3 Pfizer Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Pfizer Cardiovascular Disease Drugs Products Offered
11.3.5 Pfizer Related Developments
11.4 Sanofi
11.4.1 Sanofi Corporation Information
11.4.2 Sanofi Description and Business Overview
11.4.3 Sanofi Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Sanofi Cardiovascular Disease Drugs Products Offered
11.4.5 Sanofi Related Developments
11.5 Merck
11.5.1 Merck Corporation Information
11.5.2 Merck Description and Business Overview
11.5.3 Merck Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Merck Cardiovascular Disease Drugs Products Offered
11.5.5 Merck Related Developments
11.6 Daiichi Sankyo Company Limited
11.6.1 Daiichi Sankyo Company Limited Corporation Information
11.6.2 Daiichi Sankyo Company Limited Description and Business Overview
11.6.3 Daiichi Sankyo Company Limited Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Daiichi Sankyo Company Limited Cardiovascular Disease Drugs Products Offered
11.6.5 Daiichi Sankyo Company Limited Related Developments
11.7 Novartis
11.7.1 Novartis Corporation Information
11.7.2 Novartis Description and Business Overview
11.7.3 Novartis Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Novartis Cardiovascular Disease Drugs Products Offered
11.7.5 Novartis Related Developments
11.8 Bayer
11.8.1 Bayer Corporation Information
11.8.2 Bayer Description and Business Overview
11.8.3 Bayer Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Bayer Cardiovascular Disease Drugs Products Offered
11.8.5 Bayer Related Developments
11.9 Takeda Pharmaceutical
11.9.1 Takeda Pharmaceutical Corporation Information
11.9.2 Takeda Pharmaceutical Description and Business Overview
11.9.3 Takeda Pharmaceutical Sales, Revenue and Gross Margin (2015-2020)
11.9.4 Takeda Pharmaceutical Cardiovascular Disease Drugs Products Offered
11.9.5 Takeda Pharmaceutical Related Developments
11.10 Hoffmann-La Roche
11.10.1 Hoffmann-La Roche Corporation Information
11.10.2 Hoffmann-La Roche Description and Business Overview
11.10.3 Hoffmann-La Roche Sales, Revenue and Gross Margin (2015-2020)
11.10.4 Hoffmann-La Roche Cardiovascular Disease Drugs Products Offered
11.10.5 Hoffmann-La Roche Related Developments
11.1 AstraZeneca
11.1.1 AstraZeneca Corporation Information
11.1.2 AstraZeneca Description and Business Overview
11.1.3 AstraZeneca Sales, Revenue and Gross Margin (2015-2020)
11.1.4 AstraZeneca Cardiovascular Disease Drugs Products Offered
11.1.5 AstraZeneca Related Developments
11.12 Actelion Pharmaceuticals
11.12.1 Actelion Pharmaceuticals Corporation Information
11.12.2 Actelion Pharmaceuticals Description and Business Overview
11.12.3 Actelion Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.12.4 Actelion Pharmaceuticals Products Offered
11.12.5 Actelion Pharmaceuticals Related Developments
11.13 Boehringer Ingelheim
11.13.1 Boehringer Ingelheim Corporation Information
11.13.2 Boehringer Ingelheim Description and Business Overview
11.13.3 Boehringer Ingelheim Sales, Revenue and Gross Margin (2015-2020)
11.13.4 Boehringer Ingelheim Products Offered
11.13.5 Boehringer Ingelheim Related Developments
11.14 Astellas Pharma
11.14.1 Astellas Pharma Corporation Information
11.14.2 Astellas Pharma Description and Business Overview
11.14.3 Astellas Pharma Sales, Revenue and Gross Margin (2015-2020)
11.14.4 Astellas Pharma Products Offered
11.14.5 Astellas Pharma Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Cardiovascular Disease Drugs Market Estimates and Projections by Region
12.1.1 Global Cardiovascular Disease Drugs Sales Forecast by Regions 2021-2026
12.1.2 Global Cardiovascular Disease Drugs Revenue Forecast by Regions 2021-2026
12.2 North America Cardiovascular Disease Drugs Market Size Forecast (2021-2026)
12.2.1 North America: Cardiovascular Disease Drugs Sales Forecast (2021-2026)
12.2.2 North America: Cardiovascular Disease Drugs Revenue Forecast (2021-2026)
12.2.3 North America: Cardiovascular Disease Drugs Market Size Forecast by Country (2021-2026)
12.3 Europe Cardiovascular Disease Drugs Market Size Forecast (2021-2026)
12.3.1 Europe: Cardiovascular Disease Drugs Sales Forecast (2021-2026)
12.3.2 Europe: Cardiovascular Disease Drugs Revenue Forecast (2021-2026)
12.3.3 Europe: Cardiovascular Disease Drugs Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Cardiovascular Disease Drugs Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Cardiovascular Disease Drugs Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Cardiovascular Disease Drugs Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Cardiovascular Disease Drugs Market Size Forecast by Region (2021-2026)
12.5 Latin America Cardiovascular Disease Drugs Market Size Forecast (2021-2026)
12.5.1 Latin America: Cardiovascular Disease Drugs Sales Forecast (2021-2026)
12.5.2 Latin America: Cardiovascular Disease Drugs Revenue Forecast (2021-2026)
12.5.3 Latin America: Cardiovascular Disease Drugs Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Cardiovascular Disease Drugs Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Cardiovascular Disease Drugs Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Cardiovascular Disease Drugs Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Cardiovascular Disease Drugs Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Cardiovascular Disease Drugs Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Cardiovascular Disease Drugs Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Table 1. Cardiovascular Disease Drugs Market Segments
Table 2. Ranking of Global Top Cardiovascular Disease Drugs Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Cardiovascular Disease Drugs Market Size Growth Rate by Type 2020-2026 (K Units) & (US$ Million)
Table 4. Major Manufacturers of Heparin
Table 5. Major Manufacturers of Coumadin
Table 6. Major Manufacturers of Sectral
Table 7. Major Manufacturers of Zebeta
Table 8. Major Manufacturers of Lopressor
Table 9. Major Manufacturers of Toprol XL
Table 10. Major Manufacturers of Norvasc
Table 11. Major Manufacturers of Lotrel
Table 12. Major Manufacturers of Others
Table 13. Global Cardiovascular Disease Drugs Market Size Growth Rate by Application 2020-2026 (K Units)
Table 14. Global Cardiovascular Disease Drugs Market Size by Region (K Units) & (US$ Million): 2020 VS 2026
Table 15. Global Cardiovascular Disease Drugs Sales by Regions 2015-2020 (K Units)
Table 16. Global Cardiovascular Disease Drugs Sales Market Share by Regions (2015-2020)
Table 17. Global Cardiovascular Disease Drugs Revenue by Regions 2015-2020 (US$ Million)
Table 18. Global Cardiovascular Disease Drugs Sales by Manufacturers (2015-2020) (K Units)
Table 19. Global Cardiovascular Disease Drugs Sales Share by Manufacturers (2015-2020)
Table 20. Global Cardiovascular Disease Drugs Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 21. Global Cardiovascular Disease Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Cardiovascular Disease Drugs as of 2019)
Table 22. Cardiovascular Disease Drugs Revenue by Manufacturers (2015-2020) (US$ Million)
Table 23. Cardiovascular Disease Drugs Revenue Share by Manufacturers (2015-2020)
Table 24. Key Manufacturers Cardiovascular Disease Drugs Price (2015-2020) (USD/Units)
Table 25. Cardiovascular Disease Drugs Manufacturers Manufacturing Base Distribution and Headquarters
Table 26. Manufacturers Cardiovascular Disease Drugs Product Type
Table 27. Date of International Manufacturers Enter into Cardiovascular Disease Drugs Market
Table 28. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 29. Global Cardiovascular Disease Drugs Sales by Type (2015-2020) (K Units)
Table 30. Global Cardiovascular Disease Drugs Sales Share by Type (2015-2020)
Table 31. Global Cardiovascular Disease Drugs Revenue by Type (2015-2020) (US$ Million)
Table 32. Global Cardiovascular Disease Drugs Revenue Share by Type (2015-2020)
Table 33. Cardiovascular Disease Drugs Average Selling Price (ASP) by Type 2015-2020 (USD/Units)
Table 34. Global Cardiovascular Disease Drugs Sales by Application (2015-2020) (K Units)
Table 35. Global Cardiovascular Disease Drugs Sales Share by Application (2015-2020)
Table 36. North America Cardiovascular Disease Drugs Sales by Country (2015-2020) (K Units)
Table 37. North America Cardiovascular Disease Drugs Sales Market Share by Country (2015-2020)
Table 38. North America Cardiovascular Disease Drugs Revenue by Country (2015-2020) (US$ Million)
Table 39. North America Cardiovascular Disease Drugs Revenue Market Share by Country (2015-2020)
Table 40. North America Cardiovascular Disease Drugs Sales by Type (2015-2020) (K Units)
Table 41. North America Cardiovascular Disease Drugs Sales Market Share by Type (2015-2020)
Table 42. North America Cardiovascular Disease Drugs Sales by Application (2015-2020) (K Units)
Table 43. North America Cardiovascular Disease Drugs Sales Market Share by Application (2015-2020)
Table 44. Europe Cardiovascular Disease Drugs Sales by Country (2015-2020) (K Units)
Table 45. Europe Cardiovascular Disease Drugs Sales Market Share by Country (2015-2020)
Table 46. Europe Cardiovascular Disease Drugs Revenue by Country (2015-2020) (US$ Million)
Table 47. Europe Cardiovascular Disease Drugs Revenue Market Share by Country (2015-2020)
Table 48. Europe Cardiovascular Disease Drugs Sales by Type (2015-2020) (K Units)
Table 49. Europe Cardiovascular Disease Drugs Sales Market Share by Type (2015-2020)
Table 50. Europe Cardiovascular Disease Drugs Sales by Application (2015-2020) (K Units)
Table 51. Europe Cardiovascular Disease Drugs Sales Market Share by Application (2015-2020)
Table 52. Asia Pacific Cardiovascular Disease Drugs Sales by Region (2015-2020) (K Units)
Table 53. Asia Pacific Cardiovascular Disease Drugs Sales Market Share by Region (2015-2020)
Table 54. Asia Pacific Cardiovascular Disease Drugs Revenue by Region (2015-2020) (US$ Million)
Table 55. Asia Pacific Cardiovascular Disease Drugs Revenue Market Share by Region (2015-2020)
Table 56. Asia Pacific Cardiovascular Disease Drugs Sales by Type (2015-2020) (K Units)
Table 57. Asia Pacific Cardiovascular Disease Drugs Sales Market Share by Type (2015-2020)
Table 58. Asia Pacific Cardiovascular Disease Drugs Sales by Application (2015-2020) (K Units)
Table 59. Asia Pacific Cardiovascular Disease Drugs Sales Market Share by Application (2015-2020)
Table 60. Latin America Cardiovascular Disease Drugs Sales by Country (2015-2020) (K Units)
Table 61. Latin America Cardiovascular Disease Drugs Sales Market Share by Country (2015-2020)
Table 62. Latin Americaa Cardiovascular Disease Drugs Revenue by Country (2015-2020) (US$ Million)
Table 63. Latin America Cardiovascular Disease Drugs Revenue Market Share by Country (2015-2020)
Table 64. Latin America Cardiovascular Disease Drugs Sales by Type (2015-2020) (K Units)
Table 65. Latin America Cardiovascular Disease Drugs Sales Market Share by Type (2015-2020)
Table 66. Latin America Cardiovascular Disease Drugs Sales by Application (2015-2020) (K Units)
Table 67. Latin America Cardiovascular Disease Drugs Sales Market Share by Application (2015-2020)
Table 68. Middle East and Africa Cardiovascular Disease Drugs Sales by Country (2015-2020) (K Units)
Table 69. Middle East and Africa Cardiovascular Disease Drugs Sales Market Share by Country (2015-2020)
Table 70. Middle East and Africa Cardiovascular Disease Drugs Revenue by Country (2015-2020) (US$ Million)
Table 71. Middle East and Africa Cardiovascular Disease Drugs Revenue Market Share by Country (2015-2020)
Table 72. Middle East and Africa Cardiovascular Disease Drugs Sales by Type (2015-2020) (K Units)
Table 73. Middle East and Africa Cardiovascular Disease Drugs Sales Market Share by Type (2015-2020)
Table 74. Middle East and Africa Cardiovascular Disease Drugs Sales by Application (2015-2020) (K Units)
Table 75. Middle East and Africa Cardiovascular Disease Drugs Sales Market Share by Application (2015-2020)
Table 76. AstraZeneca Corporation Information
Table 77. AstraZeneca Description and Major Businesses
Table 78. AstraZeneca Cardiovascular Disease Drugs Production (K Units), Revenue (US$ Million), Price (USD/Units) and Gross Margin (2015-2020)
Table 79. AstraZeneca Product
Table 80. AstraZeneca Recent Development
Table 81. Johnson＆Johnson Corporation Information
Table 82. Johnson＆Johnson Description and Major Businesses
Table 83. Johnson＆Johnson Cardiovascular Disease Drugs Production (K Units), Revenue (US$ Million), Price (USD/Units) and Gross Margin (2015-2020)
Table 84. Johnson＆Johnson Product
Table 85. Johnson＆Johnson Recent Development
Table 86. Pfizer Corporation Information
Table 87. Pfizer Description and Major Businesses
Table 88. Pfizer Cardiovascular Disease Drugs Production (K Units), Revenue (US$ Million), Price (USD/Units) and Gross Margin (2015-2020)
Table 89. Pfizer Product
Table 90. Pfizer Recent Development
Table 91. Sanofi Corporation Information
Table 92. Sanofi Description and Major Businesses
Table 93. Sanofi Cardiovascular Disease Drugs Production (K Units), Revenue (US$ Million), Price (USD/Units) and Gross Margin (2015-2020)
Table 94. Sanofi Product
Table 95. Sanofi Recent Development
Table 96. Merck Corporation Information
Table 97. Merck Description and Major Businesses
Table 98. Merck Cardiovascular Disease Drugs Production (K Units), Revenue (US$ Million), Price (USD/Units) and Gross Margin (2015-2020)
Table 99. Merck Product
Table 100. Merck Recent Development
Table 101. Daiichi Sankyo Company Limited Corporation Information
Table 102. Daiichi Sankyo Company Limited Description and Major Businesses
Table 103. Daiichi Sankyo Company Limited Cardiovascular Disease Drugs Production (K Units), Revenue (US$ Million), Price (USD/Units) and Gross Margin (2015-2020)
Table 104. Daiichi Sankyo Company Limited Product
Table 105. Daiichi Sankyo Company Limited Recent Development
Table 106. Novartis Corporation Information
Table 107. Novartis Description and Major Businesses
Table 108. Novartis Cardiovascular Disease Drugs Production (K Units), Revenue (US$ Million), Price (USD/Units) and Gross Margin (2015-2020)
Table 109. Novartis Product
Table 110. Novartis Recent Development
Table 111. Bayer Corporation Information
Table 112. Bayer Description and Major Businesses
Table 113. Bayer Cardiovascular Disease Drugs Production (K Units), Revenue (US$ Million), Price (USD/Units) and Gross Margin (2015-2020)
Table 114. Bayer Product
Table 115. Bayer Recent Development
Table 116. Takeda Pharmaceutical Corporation Information
Table 117. Takeda Pharmaceutical Description and Major Businesses
Table 118. Takeda Pharmaceutical Cardiovascular Disease Drugs Production (K Units), Revenue (US$ Million), Price (USD/Units) and Gross Margin (2015-2020)
Table 119. Takeda Pharmaceutical Product
Table 120. Takeda Pharmaceutical Recent Development
Table 121. Hoffmann-La Roche Corporation Information
Table 122. Hoffmann-La Roche Description and Major Businesses
Table 123. Hoffmann-La Roche Cardiovascular Disease Drugs Production (K Units), Revenue (US$ Million), Price (USD/Units) and Gross Margin (2015-2020)
Table 124. Hoffmann-La Roche Product
Table 125. Hoffmann-La Roche Recent Development
Table 126. United Therapeutics Corporation Corporation Information
Table 127. United Therapeutics Corporation Description and Major Businesses
Table 128. United Therapeutics Corporation Cardiovascular Disease Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Units) and Gross Margin (2015-2020)
Table 129. United Therapeutics Corporation Product
Table 130. United Therapeutics Corporation Recent Development
Table 131. Actelion Pharmaceuticals Corporation Information
Table 132. Actelion Pharmaceuticals Description and Major Businesses
Table 133. Actelion Pharmaceuticals Cardiovascular Disease Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Units) and Gross Margin (2015-2020)
Table 134. Actelion Pharmaceuticals Product
Table 135. Actelion Pharmaceuticals Recent Development
Table 136. Boehringer Ingelheim Corporation Information
Table 137. Boehringer Ingelheim Description and Major Businesses
Table 138. Boehringer Ingelheim Cardiovascular Disease Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Units) and Gross Margin (2015-2020)
Table 139. Boehringer Ingelheim Product
Table 140. Boehringer Ingelheim Recent Development
Table 141. Astellas Pharma Corporation Information
Table 142. Astellas Pharma Description and Major Businesses
Table 143. Astellas Pharma Cardiovascular Disease Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Units) and Gross Margin (2015-2020)
Table 144. Astellas Pharma Product
Table 145. Astellas Pharma Recent Development
Table 146. Global Cardiovascular Disease Drugs Sales Forecast by Regions (2021-2026) (K Units)
Table 147. Global Cardiovascular Disease Drugs Sales Market Share Forecast by Regions (2021-2026)
Table 148. Global Cardiovascular Disease Drugs Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 149. Global Cardiovascular Disease Drugs Revenue Market Share Forecast by Regions (2021-2026)
Table 150. North America: Cardiovascular Disease Drugs Sales Forecast by Country (2021-2026) (K Units)
Table 151. North America: Cardiovascular Disease Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 152. Europe: Cardiovascular Disease Drugs Sales Forecast by Country (2021-2026) (K Units)
Table 153. Europe: Cardiovascular Disease Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 154. Asia Pacific: Cardiovascular Disease Drugs Sales Forecast by Region (2021-2026) (K Units)
Table 155. Asia Pacific: Cardiovascular Disease Drugs Revenue Forecast by Region (2021-2026) (US$ Million)
Table 156. Latin America: Cardiovascular Disease Drugs Sales Forecast by Country (2021-2026) (K Units)
Table 157. Latin America: Cardiovascular Disease Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 158. Middle East and Africa: Cardiovascular Disease Drugs Sales Forecast by Country (2021-2026) (K Units)
Table 159. Middle East and Africa: Cardiovascular Disease Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 160. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 161. Key Challenges
Table 162. Market Risks
Table 163. Main Points Interviewed from Key Cardiovascular Disease Drugs Players
Table 164. Cardiovascular Disease Drugs Customers List
Table 165. Cardiovascular Disease Drugs Distributors List
Table 166. Research Programs/Design for This Report
Table 167. Key Data Information from Secondary Sources
Table 168. Key Data Information from Primary Sources
List of Figures
Figure 1. Cardiovascular Disease Drugs Product Picture
Figure 2. Global Cardiovascular Disease Drugs Sales Market Share by Type in 2020 & 2026
Figure 3. Heparin Product Picture
Figure 4. Coumadin Product Picture
Figure 5. Sectral Product Picture
Figure 6. Zebeta Product Picture
Figure 7. Lopressor Product Picture
Figure 8. Toprol XL Product Picture
Figure 9. Norvasc Product Picture
Figure 10. Lotrel Product Picture
Figure 11. Others Product Picture
Figure 12. Global Cardiovascular Disease Drugs Sales Market Share by Application in 2020 & 2026
Figure 13. Asischemic Heart Disease
Figure 14. Dyslipidemia
Figure 15. Stroke
Figure 16. Thrombosis
Figure 17. Atherosclerosis
Figure 18. Coronary Artery Diseases
Figure 19. Peripheral Artery Disease
Figure 20. Others
Figure 21. Cardiovascular Disease Drugs Report Years Considered
Figure 22. Global Cardiovascular Disease Drugs Market Size 2015-2026 (US$ Million)
Figure 23. Global Cardiovascular Disease Drugs Sales 2015-2026 (K Units)
Figure 24. Global Cardiovascular Disease Drugs Market Size Market Share by Region: 2020 Versus 2026
Figure 25. Global Cardiovascular Disease Drugs Sales Market Share by Region (2015-2020)
Figure 26. Global Cardiovascular Disease Drugs Sales Market Share by Region in 2019
Figure 27. Global Cardiovascular Disease Drugs Revenue Market Share by Region (2015-2020)
Figure 28. Global Cardiovascular Disease Drugs Revenue Market Share by Region in 2019
Figure 29. Global Cardiovascular Disease Drugs Sales Share by Manufacturer in 2019
Figure 30. The Top 10 and 5 Players Market Share by Cardiovascular Disease Drugs Revenue in 2019
Figure 31. Cardiovascular Disease Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 32. Global Cardiovascular Disease Drugs Sales Market Share by Type (2015-2020)
Figure 33. Global Cardiovascular Disease Drugs Sales Market Share by Type in 2019
Figure 34. Global Cardiovascular Disease Drugs Revenue Market Share by Type (2015-2020)
Figure 35. Global Cardiovascular Disease Drugs Revenue Market Share by Type in 2019
Figure 36. Global Cardiovascular Disease Drugs Market Share by Price Range (2015-2020)
Figure 37. Global Cardiovascular Disease Drugs Sales Market Share by Application (2015-2020)
Figure 38. Global Cardiovascular Disease Drugs Sales Market Share by Application in 2019
Figure 39. Global Cardiovascular Disease Drugs Revenue Market Share by Application (2015-2020)
Figure 40. Global Cardiovascular Disease Drugs Revenue Market Share by Application in 2019
Figure 41. North America Cardiovascular Disease Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 42. North America Cardiovascular Disease Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 43. North America Cardiovascular Disease Drugs Sales Market Share by Country in 2019
Figure 44. North America Cardiovascular Disease Drugs Revenue Market Share by Country in 2019
Figure 45. U.S. Cardiovascular Disease Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 46. U.S. Cardiovascular Disease Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 47. Canada Cardiovascular Disease Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 48. Canada Cardiovascular Disease Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 49. North America Cardiovascular Disease Drugs Market Share by Type in 2019
Figure 50. North America Cardiovascular Disease Drugs Market Share by Application in 2019
Figure 51. Europe Cardiovascular Disease Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 52. Europe Cardiovascular Disease Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 53. Europe Cardiovascular Disease Drugs Sales Market Share by Country in 2019
Figure 54. Europe Cardiovascular Disease Drugs Revenue Market Share by Country in 2019
Figure 55. Germany Cardiovascular Disease Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 56. Germany Cardiovascular Disease Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 57. France Cardiovascular Disease Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 58. France Cardiovascular Disease Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 59. U.K. Cardiovascular Disease Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 60. U.K. Cardiovascular Disease Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 61. Italy Cardiovascular Disease Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 62. Italy Cardiovascular Disease Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 63. Russia Cardiovascular Disease Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 64. Russia Cardiovascular Disease Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 65. Europe Cardiovascular Disease Drugs Market Share by Type in 2019
Figure 66. Europe Cardiovascular Disease Drugs Market Share by Application in 2019
Figure 67. Asia Pacific Cardiovascular Disease Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 68. Asia Pacific Cardiovascular Disease Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 69. Asia Pacific Cardiovascular Disease Drugs Sales Market Share by Region in 2019
Figure 70. Asia Pacific Cardiovascular Disease Drugs Revenue Market Share by Region in 2019
Figure 71. China Cardiovascular Disease Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 72. China Cardiovascular Disease Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 73. Japan Cardiovascular Disease Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 74. Japan Cardiovascular Disease Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 75. South Korea Cardiovascular Disease Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 76. South Korea Cardiovascular Disease Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 77. India Cardiovascular Disease Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 78. India Cardiovascular Disease Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 79. Australia Cardiovascular Disease Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 80. Australia Cardiovascular Disease Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 81. Taiwan Cardiovascular Disease Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 82. Taiwan Cardiovascular Disease Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 83. Indonesia Cardiovascular Disease Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 84. Indonesia Cardiovascular Disease Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 85. Thailand Cardiovascular Disease Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 86. Thailand Cardiovascular Disease Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 87. Malaysia Cardiovascular Disease Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 88. Malaysia Cardiovascular Disease Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 89. Philippines Cardiovascular Disease Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 90. Philippines Cardiovascular Disease Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 91. Vietnam Cardiovascular Disease Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 92. Vietnam Cardiovascular Disease Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 93. Asia Pacific Cardiovascular Disease Drugs Market Share by Type in 2019
Figure 94. Asia Pacific Cardiovascular Disease Drugs Market Share by Application in 2019
Figure 95. Latin America Cardiovascular Disease Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 96. Latin America Cardiovascular Disease Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 97. Latin America Cardiovascular Disease Drugs Sales Market Share by Country in 2019
Figure 98. Latin America Cardiovascular Disease Drugs Revenue Market Share by Country in 2019
Figure 99. Mexico Cardiovascular Disease Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 100. Mexico Cardiovascular Disease Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 101. Brazil Cardiovascular Disease Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 102. Brazil Cardiovascular Disease Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 103. Argentina Cardiovascular Disease Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 104. Argentina Cardiovascular Disease Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 105. Latin America Cardiovascular Disease Drugs Market Share by Type in 2019
Figure 106. Latin America Cardiovascular Disease Drugs Market Share by Application in 2019
Figure 107. Middle East and Africa Cardiovascular Disease Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 108. Middle East and Africa Cardiovascular Disease Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 109. Middle East and Africa Cardiovascular Disease Drugs Sales Market Share by Country in 2019
Figure 110. Middle East and Africa Cardiovascular Disease Drugs Revenue Market Share by Country in 2019
Figure 111. Turkey Cardiovascular Disease Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 112. Turkey Cardiovascular Disease Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 113. Saudi Arabia Cardiovascular Disease Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 114. Saudi Arabia Cardiovascular Disease Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 115. U.A.E Cardiovascular Disease Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 116. U.A.E Cardiovascular Disease Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 117. Middle East and Africa Cardiovascular Disease Drugs Market Share by Type in 2019
Figure 118. Middle East and Africa Cardiovascular Disease Drugs Market Share by Application in 2019
Figure 119. North America Cardiovascular Disease Drugs Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 120. North America Cardiovascular Disease Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 121. Europe Cardiovascular Disease Drugs Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 122. Europe Cardiovascular Disease Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 123. Asia Pacific Cardiovascular Disease Drugs Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 124. Asia Pacific Cardiovascular Disease Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 125. Latin America Cardiovascular Disease Drugs Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 126. Latin America Cardiovascular Disease Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 127. Middle East and Africa Cardiovascular Disease Drugs Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 128. Middle East and Africa Cardiovascular Disease Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 129. Porter's Five Forces Analysis
Figure 130. Channels of Distribution
Figure 131. Distributors Profiles
Figure 132. Bottom-up and Top-down Approaches for This Report
Figure 133. Data Triangulation
Figure 134. Key Executives Interviewed
クラッベ病治療薬の世界市場（～2026年） Krabbe disease is an uncommon and typically deadly concern of the nervous system. It is an acquired hereditary sickness, which implies that it is passed down in families. Individuals with Krabbe disease are not able to make a sufficient substance called galactosylceramidase, which is expected to mak…- 心血管薬の世界市場（～2026年） Cardiovascular Drugs and Therapy is a bimonthly peer-reviewed medical journal covering pharmacotherapy as it relates to cardiology. It was established in 1987 and is published by Springer Science+Business Media on behalf of the International Society of Cardiovascular Pharmacotherapy, of which it is …
- 重症筋無力症治療薬の世界市場（～2026年） Myasthenia gravis is a neuromuscular disorder that leads to the weakening of skeletal muscles, which are responsible for the movement of the body. This condition occurs due to the impairment of communication between muscles and nerve cells. This impairment causes difficulties in the contraction and …
- 末梢動脈疾患（PAD）薬の世界市場（～2026年） Market Analysis and Insights: Global Peripheral Arterial Disease (PAD) Drugs Market The global Peripheral Arterial Disease (PAD) Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Peripheral Arterial Disease (PAD) D…
- メニエール病治療薬の世界市場（～2026年） Market Analysis and Insights: Global Meniere Disease Drugs Market The global Meniere Disease Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Meniere Disease Drugs Scope and Market Size Meniere Disease Drugs marke…